Cartilage Disaggregation
Autologous cartilage is mechanically disaggregated using Mytocel technology to obtain a micrograft suspension.
An orthobiologic treatment for osteoarthritis based on autologous cartilage micrografts, designed to modulate inflammation, support joint regeneration and pain management through a minimally invasive procedure.
The Mytocel MSK Procedure
A point-of-care procedure designed to prepare autologous cartilage micrografts for application to the affected joint.
for application to the affected joint.
Autologous cartilage is mechanically disaggregated using Mytocel technology to obtain a micrograft suspension.
The resulting autologous micrograft suspension is applied to the affected joint within the same clinical session.
Access detailed clinical information and hands-on training for healthcare professionals.
Clinical Comparison
Mytocel MSK provides a different approach compared to conventional biologic treatments.
| Characteristics | Mytocel MSK AMT® |
PRP
Platelet-Rich Plasma |
Hyaluronic Acid
Viscosupplementation |
Corticosteroids
Anti-inflammatory |
|---|---|---|---|---|
| Autologous Source |
|
|
|
|
| Cell-Based |
|
|
|
|
| Single Session |
|
|
|
|
| Tissue-Specific |
|
|
|
|
| Duration of Effect | 3+ years | 6 – 12 mo | 3 – 6 mo | 3 mo |
| Point-of-Care |
|
|
|
|
| Invasiveness | Minimal | Minimal | Minimal | Minimal |
